Citadel Advisors’s Melinta Therapeutics MLNT Stock Holding History
Bought
Maintained
Sold
Citadel Advisors's MLNT Position: Q1 2020 in Review
Citadel Advisors sold out of Melinta Therapeutics (MLNT) in Q1 2020, closing a stake of 56,839 shares — an estimated $30K sold.
Citadel Advisors first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $469K in Q2 2018. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.
- Citadel Advisors reported no remaining Melinta Therapeutics position as of Q1 2020 after selling out during the quarter.
- Citadel Advisors sold 56,839 Melinta Therapeutics shares in Q1 2020, an estimated $30K.
- Citadel Advisors first reported a position in Melinta Therapeutics in Q4 2017 and held it in 9 quarters.
- Citadel Advisors's Melinta Therapeutics position peaked at $469K in Q2 2018.
- 2 funds tracked by Wall St. Rank held Melinta Therapeutics as of Q1 2020.
Based on Citadel Advisors's 13F filing for Q1 2020, filed 15 May 2020.